DK1326634T3 - Vaccinepræparat der omfatter et antigen og et peptid med adjuvansegenskaber - Google Patents

Vaccinepræparat der omfatter et antigen og et peptid med adjuvansegenskaber

Info

Publication number
DK1326634T3
DK1326634T3 DK01980496T DK01980496T DK1326634T3 DK 1326634 T3 DK1326634 T3 DK 1326634T3 DK 01980496 T DK01980496 T DK 01980496T DK 01980496 T DK01980496 T DK 01980496T DK 1326634 T3 DK1326634 T3 DK 1326634T3
Authority
DK
Denmark
Prior art keywords
peptide
antigen
amino acid
acid residue
vaccine composition
Prior art date
Application number
DK01980496T
Other languages
English (en)
Inventor
Joerg Fritz
Frank Mattner
Michael Buschle
Wolfgang Zauner
Eszter Nagy
Original Assignee
Intercell Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercell Ag filed Critical Intercell Ag
Application granted granted Critical
Publication of DK1326634T3 publication Critical patent/DK1326634T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DK01980496T 2000-10-18 2001-10-18 Vaccinepræparat der omfatter et antigen og et peptid med adjuvansegenskaber DK1326634T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0178900A AT410635B (de) 2000-10-18 2000-10-18 Vakzin-zusammensetzung

Publications (1)

Publication Number Publication Date
DK1326634T3 true DK1326634T3 (da) 2006-08-14

Family

ID=3688953

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01980496T DK1326634T3 (da) 2000-10-18 2001-10-18 Vaccinepræparat der omfatter et antigen og et peptid med adjuvansegenskaber

Country Status (27)

Country Link
US (3) US8361476B2 (da)
EP (1) EP1326634B1 (da)
JP (2) JP4227407B2 (da)
KR (1) KR100598302B1 (da)
CN (1) CN1248736C (da)
AT (2) AT410635B (da)
AU (2) AU2002212326B2 (da)
BR (1) BRPI0114994B8 (da)
CA (1) CA2426490C (da)
CZ (1) CZ303303B6 (da)
DE (1) DE60119145T2 (da)
DK (1) DK1326634T3 (da)
ES (1) ES2263668T3 (da)
HK (1) HK1055899A1 (da)
HU (1) HU228382B1 (da)
IL (2) IL154605A0 (da)
IS (1) IS2608B (da)
MX (1) MXPA03002828A (da)
NO (1) NO330274B1 (da)
NZ (1) NZ524532A (da)
PL (1) PL209016B1 (da)
PT (1) PT1326634E (da)
RU (2) RU2328305C2 (da)
SI (1) SI1326634T1 (da)
SK (1) SK287618B6 (da)
WO (1) WO2002032451A1 (da)
ZA (1) ZA200301465B (da)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT410635B (de) * 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
US7244438B2 (en) 2001-01-05 2007-07-17 Intercell Ag Uses for polycationic compounds
WO2002053184A2 (en) * 2001-01-05 2002-07-11 Intercell Ag Uses for polycationic compounds as vaccine adjuvants
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
EP1279404A1 (en) * 2001-07-26 2003-01-29 Istituto Superiore di Sanità Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
EP1523557A2 (en) 2002-07-24 2005-04-20 Intercell AG Antigens encoded by alternative reading frame from pathogenic viruses
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
EP2402026A3 (en) 2002-09-13 2012-04-18 Intercell AG Method for isolating hepatitis C virus peptides
AU2003274011B2 (en) 2002-10-15 2010-03-04 Intercell Ag Nucleic acids coding for adhesion factor of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof
DK1601770T3 (da) 2003-03-04 2009-11-02 Intercell Ag Streptococcus pyogenes antigener
WO2004084937A1 (en) * 2003-03-24 2004-10-07 Intercell Ag Use of alum and a th1 immune response inducing adjuvant for enhancing immune responses
WO2004084938A1 (en) * 2003-03-24 2004-10-07 Intercell Ag Improved vaccines
AU2004226262A1 (en) 2003-03-31 2004-10-14 Intercell Ag Staphylococcus epidermidis antigens
EP2311989A1 (en) 2003-04-15 2011-04-20 Intercell AG S. pneumoniae antigens
US8076059B2 (en) * 2003-04-16 2011-12-13 Duke University Adjuvant capable of specifically activating the adaptive immune response
JP2007535894A (ja) 2003-05-07 2007-12-13 インターツェル・アクチェンゲゼルシャフト ストレプトコッカス・アガラクティエ抗原ｉ＋ｉｉ
CN102304527A (zh) 2003-05-30 2012-01-04 英特塞尔股份公司 肠球菌抗原
PL1648502T3 (pl) * 2003-07-11 2011-05-31 Intercell Ag Szczepionki przeciwko HCV
US20080145383A1 (en) 2004-03-12 2008-06-19 Intercell Ag Method for Solubilizing Peptide Mixtures
EP1791858B1 (en) 2004-09-24 2010-04-21 Intercell AG Modified vp1-capsid protein of parvovirus b19
EP1931379B1 (en) 2005-10-07 2013-05-29 Health Protection Agency Proteins with improved solubility and methods for producing and using same
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
EP2402024A1 (en) 2006-06-28 2012-01-04 Statens Serum Institut Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails
EP2287189A1 (en) 2006-07-07 2011-02-23 Intercell AG Small Streptococcus pyogenes antigens and their use
CA2661224A1 (en) 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
EP1923069A1 (en) 2006-11-20 2008-05-21 Intercell AG Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
EP2266592A3 (en) 2007-01-12 2012-08-08 Intercell AG Protective proteins of S. agalactiae, combinations thereof and methods of using the same
CA2685805A1 (en) 2007-05-02 2008-11-13 Intercell Ag Klebsiella antigens
EP2012122A1 (en) 2007-07-06 2009-01-07 Medigene AG Mutated parvovirus structural proteins as vaccines
EP2158211B1 (en) 2007-05-31 2016-08-10 Medigene AG Mutated structural protein of a parvovirus
EP2167530A2 (en) 2007-06-18 2010-03-31 Intercell AG Chlamydia antigens
US8241643B2 (en) 2008-03-17 2012-08-14 Intercell Ag Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
US8287887B2 (en) 2008-04-02 2012-10-16 The University Of Tokushima Antigen-and-drug vehicle comprising synthetic peptide, and mucosal vaccine using the same
EP2303318A2 (en) 2008-06-20 2011-04-06 Wyeth LLC Compositions and methods of use of orf1358 from beta-hemolytic streptococcal strains
US20100015171A1 (en) * 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
US20130243779A1 (en) 2009-02-05 2013-09-19 Intercell Ag Peptides protective against e. faecalis, methods and uses relating thereto
EP2405938A2 (en) 2009-02-13 2012-01-18 Intercell AG Nontypable haemophilus influenzae antigens
BRPI1015567A2 (pt) 2009-06-22 2021-08-31 Wyeth Llc Composições imunogênicas de antígenos de staphylococcus aureus
NZ597191A (en) 2009-06-22 2013-11-29 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
CA2772103A1 (en) 2009-08-27 2011-03-03 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
EP2319871A1 (en) 2009-11-05 2011-05-11 Sanofi-aventis Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
CN102686611A (zh) 2009-10-09 2012-09-19 赛诺菲 与“渐进性糖化终产物受体”结合的多肽以及包括所述多肽的组合物和方法
EP2308896A1 (en) 2009-10-09 2011-04-13 Sanofi-aventis Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
WO2011101465A1 (en) 2010-02-19 2011-08-25 Intercell Ag Ic31 nanoparticles
CA2793510A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
EP2575870B1 (en) 2010-06-04 2016-12-07 Wyeth LLC Vaccine formulations
EP3246044B2 (en) 2010-08-23 2024-04-10 Wyeth LLC Stable formulations of neisseria meningitidis rlp2086 antigens
EP2753352B2 (en) 2010-09-03 2022-08-10 Valneva Austria GmbH Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof
WO2012031760A1 (en) 2010-09-08 2012-03-15 Medigene Ag Parvovirus mutated structural proteins comprising cross - protective b - cell epitopes of a hpv l2 protein as well as products and methods relating thereto
ES2864635T3 (es) 2010-09-10 2021-10-14 Wyeth Llc Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
AU2011346535B2 (en) 2010-12-22 2015-09-24 Wyeth Llc Stable immunogenic compositions of Staphylococcus aureus antigens
BRPI1100857A2 (pt) * 2011-03-18 2013-05-21 Alexandre Eduardo Nowill agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
ITMI20111182A1 (it) 2011-06-28 2012-12-29 Canio Buonavoglia Vaccino per coronavirus canino
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY167723A (en) 2012-03-09 2018-09-21 Pfizer Neisseria meningitidis compositions and methods thereof
AU2013259598B2 (en) * 2012-05-08 2018-10-04 Western University Of Health Sciences Standardized ex vivo platforms for the antigen-specific expansion of CD4+ T cell populations
CN109364244B (zh) * 2012-10-29 2022-04-29 阿肯色大学评议会 黏膜佐剂和递送系统
EP4169929A1 (en) 2012-12-20 2023-04-26 Pfizer Inc. Immunogenic compositions comprising pn-serotype 12f
ES2685894T3 (es) 2013-03-08 2018-10-15 Pfizer Inc. Polipéptidos de fusión inmunogénicos
US20140271723A1 (en) * 2013-03-15 2014-09-18 Saint Louis University Adjuvant compositions and methods of using thereof
WO2015033251A2 (en) 2013-09-08 2015-03-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2016130569A1 (en) 2015-02-09 2016-08-18 Mj Biologics, Inc. A composition comprising pedv antigens and methods for making and using the composition
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
PE20180172A1 (es) 2015-05-04 2018-01-22 Pfizer Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos
CN113813231B (zh) * 2016-07-01 2022-06-21 四川大学 抗菌肽衍生物在制备核酸载体中的用途及核酸载体
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN107266585B (zh) * 2017-07-13 2019-08-06 陕西科技大学 一种mlh融合抗菌肽及其制备方法和应用
EP3527223A1 (en) 2018-02-16 2019-08-21 2A Pharma AB Mutated parvovirus structural protein
JP2021513840A (ja) 2018-02-16 2021-06-03 ２エー ファーマ アーベー 自己免疫疾患の処置のためのパルボウイルス構造タンパク質
CN109745556A (zh) * 2019-03-01 2019-05-14 龙阔（苏州）生物工程有限公司 一种疫苗佐剂及其应用及猪繁殖与呼吸综合征疫苗
AU2020277661A1 (en) 2019-05-20 2021-10-21 Valneva Se A subunit vaccine for treatment or prevention of a respiratory tract infection
US20230137756A1 (en) * 2020-03-30 2023-05-04 The Wistar Institute Of Anatomy And Biology Synthetic Soluble Receptor Mimics and Methods of Use for Treatment of COVID-19
EP4136095A1 (en) 2020-04-17 2023-02-22 Regents of the University of Minnesota Sars-cov-2 spike receptor binding domain and compositions and methods thereof
EP4203995A1 (en) 2020-08-26 2023-07-05 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
CN117279659A (zh) 2021-04-09 2023-12-22 瓦尔尼瓦公司 人偏肺病毒疫苗
WO2023083964A1 (en) 2021-11-11 2023-05-19 2A Pharma Ab Parvovirus structural protein against beta- and gamma-hpv
WO2024069420A2 (en) 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU702517B2 (en) * 1993-08-06 1999-02-25 Epimmune, Inc. Cloning and characterization of the complete MAGE-1 gene
JP3442824B2 (ja) * 1993-08-30 2003-09-02 理化学研究所 抗菌性ペプチド類
JP3547504B2 (ja) * 1994-11-01 2004-07-28 独立行政法人理化学研究所 新規なポリペプチド及びその用途
EP0991767A1 (en) * 1997-06-11 2000-04-12 Institut Pasteur Attenuated recombinant mycobacteria useful as immunogens or as vaccine components
WO1999009956A1 (en) * 1997-08-29 1999-03-04 Corixa Corporation Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof
CU22700A1 (es) * 1997-09-29 2001-07-31 Ct Ingenieria Genetica Biotech Formulación farmacéutica anti-viral que contiene un péptido de la proteína factor anti-lps de limulus y su uso
US20020072495A1 (en) * 2000-09-21 2002-06-13 Oleg Chertov LL-37 is an immunostimulant
AT410635B (de) * 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
WO2004084938A1 (en) * 2003-03-24 2004-10-07 Intercell Ag Improved vaccines
WO2004084937A1 (en) * 2003-03-24 2004-10-07 Intercell Ag Use of alum and a th1 immune response inducing adjuvant for enhancing immune responses
PL1648502T3 (pl) * 2003-07-11 2011-05-31 Intercell Ag Szczepionki przeciwko HCV

Also Published As

Publication number Publication date
NO330274B1 (no) 2011-03-14
PL209016B1 (pl) 2011-07-29
NO20031595D0 (no) 2003-04-08
PL362966A1 (en) 2004-11-02
JP2008222721A (ja) 2008-09-25
BRPI0114994B8 (pt) 2021-05-25
NZ524532A (en) 2004-10-29
PT1326634E (pt) 2006-09-29
US8900564B2 (en) 2014-12-02
CA2426490A1 (en) 2002-04-25
HUP0302117A3 (en) 2004-11-29
KR100598302B1 (ko) 2006-07-07
ATA17892000A (de) 2002-11-15
SI1326634T1 (sl) 2006-10-31
HUP0302117A2 (hu) 2003-09-29
AT410635B (de) 2003-06-25
CN1248736C (zh) 2006-04-05
IS6722A (is) 2003-02-20
US20130216583A1 (en) 2013-08-22
EP1326634A1 (en) 2003-07-16
IS2608B (is) 2010-04-15
US20090123486A1 (en) 2009-05-14
RU2328305C2 (ru) 2008-07-10
AU2002212326B2 (en) 2006-01-05
US8361476B2 (en) 2013-01-29
BRPI0114994B1 (pt) 2017-11-07
JP2004511528A (ja) 2004-04-15
HK1055899A1 (en) 2004-01-30
SK287618B6 (sk) 2011-04-05
IL154605A0 (en) 2003-09-17
WO2002032451A8 (en) 2002-05-23
EP1326634B1 (en) 2006-04-26
SK5752003A3 (en) 2003-12-02
HU228382B1 (en) 2013-03-28
CA2426490C (en) 2012-01-31
CZ20031299A3 (cs) 2003-10-15
ZA200301465B (en) 2004-02-24
CZ303303B6 (cs) 2012-07-25
MXPA03002828A (es) 2003-07-14
ES2263668T3 (es) 2006-12-16
IL154605A (en) 2009-05-04
NO20031595L (no) 2003-06-05
WO2002032451A1 (en) 2002-04-25
JP4227407B2 (ja) 2009-02-18
DE60119145D1 (de) 2006-06-01
US20050063978A1 (en) 2005-03-24
DE60119145T2 (de) 2007-02-01
ATE324116T1 (de) 2006-05-15
AU1232602A (en) 2002-04-29
RU2007146372A (ru) 2009-06-20
KR20030043993A (ko) 2003-06-02
CN1468109A (zh) 2004-01-14
BR0114994A (pt) 2003-09-30

Similar Documents

Publication Publication Date Title
DK1326634T3 (da) Vaccinepræparat der omfatter et antigen og et peptid med adjuvansegenskaber
PL324531A1 (en) Derivatives of cyclosporin effective against hiv virus
RU2003114434A (ru) Вакцинная композиция
EP1090039A4 (en) PEPTIC COMPOSITION AS AN IMMUNOGEN FOR TREATING ALLERGY
ATE442378T1 (de) Substituierte wt1-peptide
ZA200207992B (en) Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid for induction of an immune response to amyloid and amyloid deposits.
ATE557041T1 (de) Peptid-vakzinen gegen streptokokken der gruppe a
PT1290013E (pt) Derivados dos peptidos apo-ai/aii
CY1108570T1 (el) Gd3-μιμητικα πεπτιδια
DE60144561D1 (de) N- und/oder c-terminal mit kurzen geladenen peptidsequenzen modifizierte peptide
BR0309491A (pt) Composição de vacina, composição imunogênica, utilização de uma proteìna e7 e anticorpos neutralizantes
ES2176334T3 (es) El uso de gabapentin en el tratamiento de la ansiedad y el panico.
MXPA02012664A (es) Peptidos para la preparacion de vacunas contra bordetella pertussis y bordetella parapertussis.
EA200100314A1 (ru) Пептидные фрагменты холерного экзотоксина в или энтеротоксина в в качестве адъювантов вакцины
WO1994004565A3 (en) Ipnv vaccine
WO2001074847A3 (en) T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer
AR009840A1 (es) Preparado vacunal para la inmunocastracion revesible de mamiferos
ECSP003720A (es) Peptidos modificados y peptidomimeticos para el uso en inmunoterapia
SE0002738D0 (sv) Electric actuator